Koers Cellectis S.A. Other OTC
Aandelen
CMVLF
FR0010425595
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 16,19 mln. 17,52 mln. | Omzet 2025 * | 70,57 mln. 76,37 mln. | Marktkapitalisatie | 195 mln. 211 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -74 mln. -80,07 mln. | Nettowinst (verlies) 2025 * | -71 mln. -76,83 mln. | EV/omzet 2024 * | 12 x |
Nettoliquiditeiten 2024 * | 573K 620K | Nettoliquiditeiten 2025 * | 180 mln. 195 mln. | EV/omzet 2025 * | 0,21 x |
K/w-verhouding 2024 * |
-
| K/w-verhouding 2025 * |
-
| Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 100% |
Recentste transcriptie over Cellectis S.A.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Sourdive
FOU | Founder | 57 | 20-12-99 |
André Choulika
FOU | Founder | 59 | 20-12-99 |
Arthur Stril
DFI | Director of Finance/CFO | 35 | 01-07-18 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 75 | 05-11-20 | |
André Choulika
FOU | Founder | 59 | 20-12-99 |
David Sourdive
FOU | Founder | 57 | 20-12-99 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+29,03% | 48,16 mld. | |
-0,10% | 41,73 mld. | |
+43,45% | 41,03 mld. | |
-5,26% | 28,77 mld. | |
+11,48% | 25,59 mld. | |
-22,74% | 18,96 mld. | |
+9,06% | 12,92 mld. | |
+30,01% | 12,03 mld. | |
-1,51% | 11,77 mld. |